Summary. This report analyzes the in vitro characteristics of ~25I-insulin binding to the monocytes of nine patients with the syndromes of acanthosis nigricans and insulin resistance. The 3 Type A patients (without demonstrable autoantibodies to the insulin receptor) had decreased binding of insulin due to a decreased concentration of receptors. In these patients the residual receptors demonstrated normal dissociation kinetics, negative cooperativity, and were blocked by anti-receptor antibodies in a manner similar to normal cells. In contrast, monocytes from the 6 Type B patients (with circulating anti-receptor autoantibodies) had decreased binding of insulin due to a decrease in receptor affinity. Insulin binding to monocytes of Type B patients demonstrated accelerated rates of dissociation with no evidence of cooperative interactions among insulin receptors. When coupled with previous data, the present studies further suggest that different mechanisms account for the defects in insulin binding and insulin resistance observed in these patients.
Several patients with acanthosis nigricans and an extreme form of insulin resistance have now been described [1] [2] [3] [4] . These patients can be divided into two groups: Type A patients, who are younger females with signs of excess androgenic effects and Type B patients, who are older and have signs of autoimmune disease. Patients in both groups show severe defects in insulin-receptor binding and Type B patients have circulating antibodies which impair insulin receptor function. The clinical course in some of these patients [5, 6] and a detailed description and characterization of the autoantibodies to the insulin receptor have been reported previously [7] [8] [9] [10] [11] [12] [13] [14] [15] .
In the present study we have analyzed in greater detail the interaction of insulin with its receptor on the circulating monocytes of nine patients with these syndromes (3 Type A and 6 Type B) in order to elucidate further the pathogenesis of these syndromes.
Materials and Methods

Patients
Clinical data are summarized for the nine patients in Table 1 . Detailed clinical descriptions of patients A-1 [3] , A-3 [3] , B-1 [3] , B-2 [3] , B-3 [3] , B-4 [16] and B-6 [14] have already been published. Patients A-4 and B-5 have not been previously reported. All patients had low or undetectable levels of anti-insulin antibodies. Prior to the binding studies, patient B-6 had received no insulin therapy for 7 days whereas the other patients had received no insulin therapy for at least 14 days. Insulin binding studies in patient A-2 are not reported here since initial binding data were not complete enough to allow detailed evaluation. It is also important to emphasize that all studies shown in this report for Type B patients were performed during initial presentation to the National Institutes of Health, since both binding characteristics and clinical course have been shown to vary in follownp studies [5, 6] . Informed consent was obtained from all patients prior to study.
Insulin Binding
a. Competition Studies. Studies of insulin binding to circulating monocytes were performed as previously described [17, 18] . Briefly, crystalline porcine insulin was labeled with 125I at a specific activity of 130-200/~tCi/~tg insulin [19, 20] (0.4-0.6 1 atoms per insulin molecule). Tracer amounts of ~25t-insulin (0.2 ng/ml) were incubated with 20 x 106 mononuclear ceils and varying concentrations of unlabelled insulin in a final volume of 0.5 ml. After 3 h [23] . The competition-inhibition curves represent the actual experimental data whereas Scatchard plots and affinity profiles allow quantitation of receptor concentration and receptor affinity, respectively. More detailed descriptions of these three methods of data presentation have been reported previously [22, 23] .
b. Cooperativity Experiments. For the cooperativity experiments the patient's mononuclear cells were first incubated with 0.2 ng/ml of 12~I-porcine insulin for 180 min at 22 ~ in Hepes buffer (pH 8.0). Aliquots, 100 Ixl, of the incubation mixture were then added to 10 ml of buffer ("dilution only") and to buffer plus 10 -7 mol/l unlabelled porcine insulin ("dilution + unlabelled insulin") and maintained at 15 ~ or 22 ~ At 0 min, 30 rain, and 60 rain, the tubes were centrifuged at 1000 g for 3 min, the supernatant was aspirated and discarded, and the radioactivity in the cell pellet was cotmted. At each time point, % 125I-insulin in the pellet (receptorbound) was then expressed as % receptor-bound insulin at time 0 [24] .
c. Effect of Antireceptor Antibodies. To demonstrate the effect of
Type B sera (containing anti-receptor antibodies) on monocyte receptors, the patient's monocytes and monocytes from normal subjects were first exposed to Type B serum for 2 h at 22 ~ washed extensively in serum-free buffer and then incubated with 125I-insulin for measurement of specific insulin binding [2] .
Results
Type A Patients
The monocytes of all Type A patients showed a marked decrease in the binding of 125I-insulin. With tracer concentration (0.2 ng/ml) binding ranged from 20% of the normal mean in patient A-1 to 60% of normal in patient A-4 ( Fig. 1 ). For each patient, % decrease in binding was generally uniform over the entire range of insulin concentrations. Scatchard plots were curvilinear with upward concavity, which is typical of all insulin receptors ( Fig. 1, center) . Fifty-percent inhibition of maximal binding was achieved with insulin concentrations of 5-10ng/ml in the three type A patients (normal range 1.2-12 ng/ml) indicating that receptor affinity was unchanged. The lack of affinity change is further emphasized by the average affinity profiles (Fig. 1,  right) . At all levels of receptor occupancy the average affinity profiles were within normal limits in the Type A patients.
Cooperativity Studies. Insulin receptors of two of the three Type A patients (A-1, A-4), were evaluated for cooperative interactions (Fig. 2) . In both patients, the dissociation rate was accelerated in the presence of 10 -7 tool/1 insulin, consistent with the finding of receptor site-site interactions of the negatively cooperative type. Mononuclear cells were first incubated with 0.2 ng/ml of 125I-insulin for 180 min at 22 ~ Aliquots of 100 ~tl were then diluted in either 10 ml of buffer ("dilution only", closed circles) or buffer + 10 -v mol/1 insulin ("dilution + unlabelled insulin", open circles) for periods up to 120 minutes. At each time point assay tubes were centrifuged, the cell-associated radioactivity was counted and expressed as a percent of the receptor-bound 125I-insulin at time 0 125I-insulin bound • 100 125I-insulin bound at t=O Effect of Fasting on Type A Patients. Two patients, A-3 and A-4, were fasted for 72 h with monocyte binding studies performed at the beginning and end of the fast. tn both cases, plasma insulin levels fell markedly (in patient A-3 200 ~tU/ml to 10 ~tU/ml and A-4 128 ~tU/ml to 30 ~tU/ml); however, insulin binding was unchanged at the end of the fast (Fig. 3,  left) .
Effect of Antireceptor Antibodies. The effect of antireceptor antibodies (derived from type B patients) on the binding of 125I-insulin to monocytes from patient A-4 is shown in Figure 4 . Exposure of monocytes to Type B sera inhibited subsequent 125I-insulin binding. The order of inhibitory potency of the three sera was identical to that observed with monocytes from normal subjects.
Type B Patients
Competition curves of insulin binding to monocytes of six patients with the Type B form of insulin resistance and acanthosis nigricans are shown in Figure 5 . Each curve is abnormal in two respects. At the lowest concentrations of insulin (0.2 ng/ml) insulin binding was only 5-25% of normal (mean). Second, the concentrations of insulin required to reduce maximal binding by 50% were markedly elevated. This latter finding was difficult to quantify in patients B-2 and B-3 since the specific binding of 125I-insulin was so low. However, in the other four patients (B-l, B-4, B-5 and B-6), some estimate could be obtained either by performing multiple binding studies or by increasing the concentration of cells (Fig. 6 ). In the Type B patients the amount of insulin required to decrease maximal binding by 50% ranged from 500 to >1000 ng/ml. By contrast, with monocytes from Type A and normal patients, the amounts of insulin needed to decrease maximal binding by 50% ranged from 1 to 12 ng/ml.
To illustrate the quantitative analyses of the data for the Type B patients, studies for patients B-1 and B-6 are presented (Fig. 7) . Scatchard plots and average affinity profiles of these data suggest that the receptors are present in normal or increased concentration but fixed in a lower affinity state (Fig. 7,  fight) , thus accounting for the decreased binding of 125I-insulin at low insulin concentration, and the failure of competing insulin to appropriately decrease the maximal binding of 125I-insulin. Similar Scatchard plots and affinity profiles were observed in the other type B patients.
Cooperativity Experiments. The kinetics of dissociation, in the absence and presence of unlabeled insulin, were studied in three Type B patients (B-l, B-3, B-6). For patient B-3, all receptor-bound 125I-insulin dissociated in 10 rain at 22 ~ even in the absence of unlabelled insulin. In patients B-1 and B-6, the dissociation rate of receptor-bound 12sI-insulin was very rapid both in the presence and absence of 10 .7 tool/1 insulin (Fig. 8 ). This contrasts with findings in type A patients and normal subjects in whom dissociation was slower with 1:100 dilution in the absence of insulin and markedly accelerated with insulin at 10-7mol/1. The intrinsic rate of dissociation of Effect of Fasting. One Type B patient has been studied before and after a 60 h fast. After fasting, plasma insulin concentration fell from an initial 125 ~U/ml to <5 ~tU/ml; however, insulin binding characteristics were unchanged from the initial studies (Fig. 3, right) ~
Discussion
In this paper we have analyzed the basal, steady-state binding data of 125I-insulin to the circulating monocytes of patients with the Type A and Type B forms of insulin resistance and acanthosis nigricans. At the time of their initial presentation, when insulin resistance was most pronounced, both groups showed striking decreases in the binding of 125I-insulin to their circulating mononuclear cells. In Type A patients the predominant defect was a decrease in receptor concentration, whereas in the Type B patients a decrease in receptor affinity predominated. In addition, the kinetics of dissociation further indicated that different mechanisms account for the binding defects in the two patient groups. The cause of the decrease in receptor concentration and the accompanying insulin resistance in the Type A patients is unknown. In addition to the Type A patients, there are several other conditions characterized by decreases in the concentration of insulin receptors on circulating cells. These include obesity [17, [25] [26] [27] [28] [29] [30] [31] , functioning islet cell tumours (insulinoma) [32] and acromegaly [33] . In human and animal obesity, clinical insulin resistance is associated with a decreased concentration of insulin receptors, the magnitude of the receptor concentration decrease being proportional to basal levels of circulating insulin and the degree of insulin resistance. When obese patients are acutely fasted their plasma insulin levels fall and there is an increase in receptor affinity [17] . More prolonged food restriction produces an increase in receptor concentration toward the normal range [17] . In Type A patients, basal levels of plasma insulin were higher than in obese patients and the cellular concentrations of insulin receptors were proportionately decreased. In contrast to the obese patients, acute periods of fasting were not associated with any change in insulin binding despite decreased ambient levels of insulin, suggesting a primary receptor defect in the monocytes of the Type A patients.
The clinical characteristics of Type A patients can also be associated with other cellular defects [34] [35] [36] . We have evaluated a young woman with acanthosis nigricans, virilization and extreme insulin resistance. In contrast to the Type A patients, monocyte receptors for insulin were entirely normal, suggesting a postreceptor or intracellular defect [34, 35] . Whether this latter patient represents a form fruste of the Type A patients, or alternatively, whether there are a spectrum of diseases with differing underlying mechanisms but similar clinical presentation is uncertain at the present time.
The relationship of acanthosis nigricans to insulin resistance is striking. All Type A patients had the dermatologic condition acanthosis nigricans at the time of initial presentation. Subsequently, one patient had complete and another partial remission of acanthosis nigricans associated with exogenous estrogen therapy; however, insulin resistance and the monocyte binding defect persisted. These findings suggest that the factors resulting in acanthosis nigricans are different from those accounting for the insulin resistance in the Type A patients.
The pathogenesis of the insulin resistance in the Type B patient is better understood. Several diverse lines of evidence implicate the anti-receptor autoantibodies as the major cause of the insulin resistance. First, exposure Of normal human monocytes, rat adipocytes and lymphoblastoid cells to the receptor autoantibodies results in a binding defect that is characterized by a decrease in receptor affinity, similar to the defect found on patient monocytes [8, 10, 37] . Second, in vitro procedures which elute surface immunoglobulins from the monocytes of Type B patients result in an increased binding of insulin and restore receptor affinity to normal [37] . In addition, we have recently performed multiple plasma exchanges in one Type B patient which resulted in progressive decreases in plasma levels of antireceptor antibodies and sequential increases in the affinity of monocyte receptors for insulin [14] . Third, in subsequent followup studies, several Type B patients have shown reversal of their insulin resistance [5, 6] . This apparent increased sensitivity to insulin was accompanied by an increased binding of insulin to circulating monocytes and, often, alterations in the titre or character of the circulating autoantibodies [5, 6] . Finally, long-term culture of fibroblasts and lymphocytes derived from the Type B patients demonstrated characteristics of insulin binding which were similar to cell cultures derived from normal individuals indicating that the binding defects do not represent a fixed component of all cells [37] . Taken together, these findings suggest that the insulin receptor in the Type B patients is normal.
The presence of "low affinity" receptors 1 in circulating monocytes is not unique to the Type B patients but has also been found in certain patients with ataxia telangiectasia [38, 39] . These patients had insulin resistance and were found to have circulating 8S IgM immunoglobulins which inhibited binding to insulin receptors. Thus, circulating autoantibodies against the insulin receptor are present in two distinct syndromes of insulin resistance (Type B patients and certain patients with ataxia telangiectasia) and result in characteristic binding defects on monocyte receptors for insulin. Although the total number of patients with autoantibodies to insulin receptors is small (-25) , the prevalence of anti-receptor antibodies as a mechanism of insulin resistance remains to be determined. Recent methodological advances in the specificity and sensitivity of autoantibody assays and their future application to other insulin resistance states should help resolve this matter [13, 15] .
